Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for ...

Company completes refinancing of all existing senior secured debt through a $120 million self-syndicated term loan with leading banks, at an interest rate of 8.3% ---- Company ...

Using the CatWalk XT system, researchers assessed ExoPTEN’s effect on the animals’ ability to walk. All animals (100%) in the higher-dose group demonstrated measurable gait recovery, in contrast to ...

While the MCTO restricts all trading in securities of the Company by executive officers of the Company until the MCTO is no longer in effect, regular trading by current and future investors outside ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, July 9, to discuss these clinical data. Participants may register for the ...

On Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time, the company will host a conference call to discuss its preliminary second quarter 2025 revenue results and revised full year guidance. To ...

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901. A replay of the call will also be available on the ...

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for ...

J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering.